AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital

Size: px
Start display at page:

Download "AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital"

Transcription

1 AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital

2 AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure and rescue strategies Interactive case study

3 AHSCT in first line therapy H97-HR trial for high risk advanced HL (Arakelyan et al. 1 ): VABEM+RT vs 4xABVD+BEAM and AHSCT; 158 pts. FFTF 79% vs 75%; OS 87% vs 5 years HD01 trial for high risk advanced HL responding to ABVD (Federico et al. 2 and Carella et al. 3 ): 4 x conventional therapy vs AHSCT FFS 75% vs 79%; OS 84% vs 10 years no role for AHSCT in first line for patients responding to initial therapy! 1. Arakelyan et al. Cancer Dec 15;113(12): Federico et al. J Clin Oncol Jun 15;21(12): Carella et al. Haematologica Jan;94(1): Epub 2008 Nov 10.

4 AHSCT for relapsed/refractory HL patients BNLI (Linch et al. 1 ): BEAM versus minibeam, 40 pts. 3years 53% versus 10%, (p=0,025) Years after randomisation Years after randomisation 1. Linch et al., Lancet Apr 24;341(8852):

5 AHSCT for relapsed/refractory HL patients HDR1 (Schmitz et al. 1 ): 4x DexaBEAM vs 2x DexaBEAM + BEAM and AHSCT, 166 pts. 3 years 34% vs 55% (p=0,019) 1. Schmitz et al., Lancet Jun 15;359(9323):

6 AHSCT for relapsed/refractory HL patients 2 cycles induction Ctx plus HDCT/APBSCT is standard of care, but 3 years still is poor (around 50%)

7 Cologne dose-intensification strategy 2x DHAP + G-CSF PR or CR: continue Single agent HD Ctx - Cyclophosphamide - Mtx, Vcr - Etoposide BEAM + APBSCT

8 HDR2: Objectives and endpoints Objective: To improve the FFTF2 by 20% using additional sequential HDCT as compared to 2x DHAP + BEAM/APBSCT Endpoints: Freedom from treatment failure (FFTF) (primary) Progression free survival (PFS) Overall survival (OS) CR/CRu rate Severe toxicities (WHO grade 3/4) Secondary neoplasms

9 D H A P PBSC R E G I S T R A T I O N HDR2: European multicenter study (GHSG, EORTC) for relapsed HL Primary refractory and DAHP refractory patients were not included SD, PR, CR B E A M C Y C M T X VP 16 B E A M R A N D O M I S A T I O N Radiotherapy to residual disease D H A P Standard: 119 pts. Intensified: 122 pts.

10 Probability HDR2: PFS by treatment arm (final analysis 3-09) p = Standard (at 3y: 72%) Intensified (at 3y: 67%) Time [months] Pts. at Risk Standard Intensified Josting et al., J Clin Oncol Dec 1;28(34): Epub 2010 Oct 25.

11 GHSG-EORTC HDR2 trial summary HDR2 trial showed no advantage of an intensified induction chemotherapy. In contrast, there were more protocol deviations Toxicities dose reductions and a longer duration of treatment 2xDHAP plus BEAM/APBSCT is a brief and highly active treatment strategy for relapsed chemosensitive HL patients with a years of 72%

12 Tandem AHSCT for high risk HL H96 (Morschhauser et al. 1 ): non-randomized trial of tandem AHSCT in high risk patients 150 poor risk, 95 intermediate risk pts. Ifosfamide-based salvage + CBV-Mx/BEAM + TAM/BAM 1. Morschhauser et al. J Clin Oncol Dec 20;26(36): Epub 2008 Nov 17.

13 Tandem AHSCT for high risk HL Poor risk: Primary refractory disease Or 2 risk factors* at first relapse Intermediate risk: One risk factor* *Risk factors: Early relapse Stage III or IV at relapse Relapse within previously irradiated sites Morschhauser et al. J Clin Oncol Dec 20;26(36): Epub 2008 Nov 17.

14 Tandem AHSCT for high risk HL H96 (Morschhauser et al. 1 ): FF2F 46% and OS OS for salvage-refractory pts. Tandem AHSCT is an option for high risk patients, especially those not reaching CR after salvage Ctx 1. Morschhauser et al. J Clin Oncol Dec 20;26(36): Epub 2008 Nov 17.

15 AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure and rescue strategies Interactive case study

16 Mobilisation failure in HL Regimen Number of patients (n) Mobilisation failure (%) Reference DHAPq2wk Josting 2002 ICE Moskowitz 2004 IGEV Santoro 2007 Josting A et al. Ann Oncol Oct;13(10): Moskowitz C et al. Br J Haematol Mar;124(5): Santoro A et al. Haematologica Jan;92(1):35-41.

17 Mobilisation failure in HL Mobilisation failure in HL is rare but challenging Rescue strategies are needed to allow for AHSCT (only curative treatment!) Tandem AHSCT highlights the need for effective mobilisation

18 Mobilisation failure in HL -rescue strategies- Alternative chemotherapy regimen (single-hd or combination) cons: toxicity, delay of AHSCT, costs pros: tumour reduction, stem cell purging (?) Bone marrow harvest cons: general anaesthesia, painful, no tumour salvage, slower engraftment, higher rate of infections pros: high rate of successful harvests Plerixafor cons: costs pros: high success rate, safe and tolerable, high stem cell yield

19 Plerixafor in HL Feasibility of mobilisation and AHSCT has been shown in a prospective phase II trial in HL patients (Cashen et al. 1 ) European compassionate use programme: 54 HL patients received plerixafor after mobilisation failure, 44 (81,5%) successfully mobilised stem cells (Huebel et al. 2 ) Plerixafor mobilisation is an effective rescue strategy in Hodgkin Lymphoma 1. Cashen et al. Biol Blood Marrow Transplant Nov;14(11): Huebel et al. Bone Marrow Transplant Aug;46(8): Epub 2010 Oct 25.

20 AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure and rescue strategies Interactive case study

21 Interactive case study Male, 21 years old, Hodgkin Lymphoma CS IIB with large mediastinal mass and involvement of left supraclavicular region Treatment: 6 x ABVD partial response (PET+) 2 x BEACOPPesc progressive disease left supraclavicular region Salvage therapy and AHSCT was planned

22 Which salvage therapy would you use? 1. DHAP? 2. ICE? 3. IGEV? 4. Dexa-BEAM? 5. None, bone marrow harvest or steady state mobilisation and straight AHSCT?

23 Which salvage therapy would you use? DHAP: well tolerated, high ORR (88%), short (2 x 2weeks), good results in the large HD-R2 study ICE: well tolerated, high ORR (85%) but high rate of mobilisation failure (in HL) IGEV: well tolerated, high ORR (81%), effective mobilisation, but long (4 x 3weeks) Dexa-BEAM: used in HD-R1 but toxic, stem cell toxic, crossresistant to BEAM Straight AHSCT: used in BNLI but disadvantages of bone marrow harvest/no salvage therapy

24 Interactive case study Salvage treatment: 3 x IGEV, no successful stem cell mobilisation Response: SD (CT-scan) Salvage radiotherapy: 30 Gy left supraclavicular region and right supraclavicular and axillary region Response: PET+ PR

25 Procedure? 1. Allogeneic transplant? 2. Mobilisation with polychemotherapy (e.g. DHAP)? 3. Mobilisation with single-hd (e.g. cyclophosphamide)? 4. Steady-state mobilisation and HDCT? 5. G-CSF + Plerixafor (with or without Ctx)?

26 Procedure? Allo-Tx: no role in HL patients before Auto-Tx Mobilisation with polychemotherapy: non-cross-resistant substances might improve the response Mobilisation with single-hd: high mobilisation potential, tumour reduction Steady state mobilisation: no further tumour reduction, lower mobilisation potential G-CSF + Plerixafor: very high mobilisation potential in combination with Ctx, suitable for poor mobilisers

27 Risk factors for poor mobilisation Age > 60 Progressive disease Severe BM involvement Previous Ctx and/or Rtx Type of Ctx Previously failed mobilisation attempts Platelet count < 100,000 /µl before apheresis Neutropenic fever during mobilisation Huebel et al., Bone Marrow Transplant 2011

28 Interactive case study 2nd salvage treatment: DHAP, no successful stem cell mobilisation the patient was admitted to our hospital

29 Procedure? 1. 2 nd mobilisation attempt with chemotherapy + G- CSF only? 2. Mobilisation with polychemotherapy + G-CSF + plerixafor? 3. Mobilisation with cyclophosphamide + G-CSF + plerixafor? 4. Mobilisation with etoposide + G-CSF + plerixafor?

30 Interactive case study Single high dose therapy: etoposide 500mg/m²/d d1-4 + lenograstim 10µg/kg BW/d

31 Interactive case study d14:plerixafor 240µg/kg BW apheresis d15: 6,591 x10 6 CD34+ cells/kg BW

32 Procedure? 1. BEAM and AHSCT? 2. Alternative regimen (e.g. CBV-Mx, Mel/Eto) and AHSCT? 3. Auto-Allo Tx? 4. Double-AHSCT (e.g. BEAM/BAM)?

33 Interactive case study Double AHSCT: 1. BEAM 2. BAM PET-CT: CR with PET- residual disease <2cm

34 Procedure? 1. Maintenance therapy? 2. No further therapy?

35 Maintenance in HL Benefit of maintenance therapy in HL has not been demonstrated (e.g. Young et al. 1 ) Currently ongoing: AETHERA (Brentuximab vedotin for HL patients after AHSCT with high risk of relapse) 1. Young et al. Lancet Jun 16;1(7816):

36 Interactive case study Final treatment outcome: patient remains in CR (follow-up: 5 years)

37 What to do in case of relapse? 1. Allo-Tx? 2. 2 nd Auto-Tx? 3. Palliative treatment with chemotherapy or experimental substance?

38 What to do in case of relapse? Allo-Tx: RIC-allo might be suitable for chemosensitive, young patients in good general condition 2nd Auto-Tx: an option for late relapse after AHSCT (Smith et al. 1 ) Palliative treatment: emerging role of new substances (HDAC-inhibitors, mtor-inhibitors and brentuximab vedotin) 1. Smith et al. Biol Blood Marrow Transplant Aug;14(8):

39 Thank you for your attention

40 AHSCT in first line therapy HD0801 trial: AHSCT in IIB-IV patients PET positive after 2 x ABVD 6 x ABVD +/-RT vs. AHSCT possible role of AHSCT in first line in the future?

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Hospital Universitari Quirón Dexeus Barcelona, Spain 9 th Educational Course on Lymphomas

More information

Confronto Real world e studi registrativi

Confronto Real world e studi registrativi Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY

More information

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational

More information

Dr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy

Dr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department

More information

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction

More information

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline

More information

German Hodgkin Study Group

German Hodgkin Study Group German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of

More information

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle

More information

ABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy

ABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat

More information

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering

More information

Hodgkin Lymphoma Status of the art of treatment

Hodgkin Lymphoma Status of the art of treatment 11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early

More information

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of

More information

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and

More information

Linfoma di Hodgkin Tra/amento dei pazien4 ricadu4

Linfoma di Hodgkin Tra/amento dei pazien4 ricadu4 Linfoma di Hodgkin Tra/amento dei pazien4 ricadu4 Simonetta Viviani SC Ematologia e Trapianto di Midollo osseo Dichiarazione Relatore: SimoneGa Viviani Posizione di dipendente in aziende con interessi

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)

More information

A CME-certified Oncology Exchange Program

A CME-certified Oncology Exchange Program A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett

More information

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy

More information

Advanced stage HL The old and new match: BEACOPP

Advanced stage HL The old and new match: BEACOPP 27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment

More information

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

Hodgkin. The PET World. Sally Barrington

Hodgkin. The PET World. Sally Barrington Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging

More information

RT in Hodgkin Lymphoma

RT in Hodgkin Lymphoma RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: 8.01.29 Last Review: 1/2019 Origination: 4/2014 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma Protocol Hematopoietic Cell Transplantation for Hodgkin Lymphoma (80129) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10, 01/11,

More information

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory

More information

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing

More information

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following

More information

Alexander Fosså, M.D. PhD.

Alexander Fosså, M.D. PhD. Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -

More information

How I treat relapsed and refractory Hodgkin lymphoma

How I treat relapsed and refractory Hodgkin lymphoma How I treat From www.bloodjournal.org by guest on September 8, 2016. For personal use only. How I treat relapsed and refractory Hodgkin lymphoma John Kuruvilla, 1,2 Armand Keating, 1,2 and Michael Crump

More information

Linfoma di Hodgkin Ruolo del trapianto nella strategia di salvataggio. Angelo Michele Carella U.O.C. Ematologia 1 IRCSS A.O.U. San Martino IST Genova

Linfoma di Hodgkin Ruolo del trapianto nella strategia di salvataggio. Angelo Michele Carella U.O.C. Ematologia 1 IRCSS A.O.U. San Martino IST Genova Linfoma di Hodgkin Ruolo del trapianto nella strategia di salvataggio Angelo Michele Carella U.O.C. Ematologia 1 IRCSS A.O.U. San Martino IST Genova Therapeutic Options for Relapsed/Refractory Patients

More information

Brentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase

Brentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE

More information

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum

More information

Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group

Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random

More information

Poor-prognostic advanced Germ Cell Tumors

Poor-prognostic advanced Germ Cell Tumors 14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: 8.01.29 Last Review: 1/2018 Origination: 4/2014 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Practical Application of PET adapted Therapy in Hodgkin Lymphoma

Practical Application of PET adapted Therapy in Hodgkin Lymphoma Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,

More information

THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)

THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International

More information

Does BV as part of salvage impact outcome?

Does BV as part of salvage impact outcome? Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our

More information

Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo

Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera

More information

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma Protocol Hematopoietic Cell Transplantation for Hodgkin Lymphoma (80129) (Formerly Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma) Medical Benefit Effective Date: 04/01/18 Next Review Date:

More information

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies

More information

At initial diagnosis, patients with

At initial diagnosis, patients with Malignant Lymphomas Decision Making and Problem Solving Current treatment and immunotherapy of Hodgkin s lymphoma Beate Klimm Roland Schnell Volker Diehl Andreas Engert The treatment of Hodgkin s lymphoma

More information

First Line Management of Classical Hodgkin Lymphoma

First Line Management of Classical Hodgkin Lymphoma First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: Original Effective Date: MM.07.015 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 4/27/2018 Section: Transplants

More information

What are the hurdles to using cell of origin in classification to treat DLBCL?

What are the hurdles to using cell of origin in classification to treat DLBCL? What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical

More information

How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma

How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del

More information

The case for maintenance rituximab in FL

The case for maintenance rituximab in FL New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P

More information

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid

More information

Elderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia

Elderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

Brentuximab Vedotin in Lymphomas

Brentuximab Vedotin in Lymphomas New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000

More information

Peripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation

Peripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011

More information

NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital

NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification

More information

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint

More information

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: Original Effective Date: MM.07.015 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 05/26/2017 Section: Transplants

More information

Peripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester

Peripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent

More information

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.

More information

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Medical Policy Manual Transplant, Policy No. 45.30 Hematopoietic Cell Transplantation for Hodgkin Lymphoma Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER

More information

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John

More information

brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd

brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

STEM CELL COLLECTION IN MOBILIZATION FAILURE

STEM CELL COLLECTION IN MOBILIZATION FAILURE STEM CELL COLLECTION IN MOBILIZATION FAILURE FEVZI ALTUNTAŞ Yıldırım Beyazıt Medical School, Ankara Oncology Hospital Department of Hematology and Bone Marrow Transplantation Unit OUTLINE Introduction

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

Transplantation for Lymphoma What is New? Siddhartha Ganguly, MD, FACP

Transplantation for Lymphoma What is New? Siddhartha Ganguly, MD, FACP Transplantation for Lymphoma What is New? Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma/Myeloma Program Division of Hematologic Malignancies and Cellular Therapeutics University

More information

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona

The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%

More information

Akiko Fukunaga, Mizuki Hyuga, Makoto Iwasaki, Yoshiki Nakae, Wataru Kishimoto, Yoshitomo Maesako, and Nobuyoshi Arima. Original Article INTRODUCTION

Akiko Fukunaga, Mizuki Hyuga, Makoto Iwasaki, Yoshiki Nakae, Wataru Kishimoto, Yoshitomo Maesako, and Nobuyoshi Arima. Original Article INTRODUCTION J Clin Exp Hematop Vol. 56, No. 1, June 216 Original Article Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization

More information

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes

More information

Mantle Cell Lymphoma

Mantle Cell Lymphoma Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.

More information

University of Padua School of Medicine, Padua, Italy; b Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

University of Padua School of Medicine, Padua, Italy; b Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA The Oncologist Lymphoma Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin s Lymphoma ANNA COLPO, a EPHRAIM HOCHBERG, b YI-BIN CHEN b a Department of Clinical and

More information

Management of high-risk diffuse large B cell lymphoma: case presentation

Management of high-risk diffuse large B cell lymphoma: case presentation Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January

More information

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing

More information

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account

More information

Published Ahead of Print on April 2, 2009 as /theoncologist Salvage Therapy in Hodgkin s Lymphoma

Published Ahead of Print on April 2, 2009 as /theoncologist Salvage Therapy in Hodgkin s Lymphoma The Oncologist Lymphoma Salvage Therapy in Hodgkin s Lymphoma JASON H. MENDLER,JONATHAN W. FRIEDBERG James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA Key

More information

Aggressive B and T cell lymphomas: Treatment paradigms in 2018

Aggressive B and T cell lymphomas: Treatment paradigms in 2018 Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

Introduction ORIGINAL PAPER. Med Oncol (2013) 30:611 DOI /s y

Introduction ORIGINAL PAPER. Med Oncol (2013) 30:611 DOI /s y Med Oncol (2013) 30:611 DOI 10.1007/s12032-013-0611-y ORIGINAL PAPER Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniformmodified BEAM-conditioning

More information

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin s lymphoma autografted after a first relapse

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin s lymphoma autografted after a first relapse Original article Annals of Oncology 16: 625 633, 2005 doi:10.1093/annonc/mdi119 Published online 28 February 2005 Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin

More information

CAR-T cell therapy pros and cons

CAR-T cell therapy pros and cons CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research

More information

Angelo Ostuni. Servizio di Immunoematologia e Medicina Trasfusionale Azienda Ospedaliera Card. Panico Tricase (LE)

Angelo Ostuni. Servizio di Immunoematologia e Medicina Trasfusionale Azienda Ospedaliera Card. Panico Tricase (LE) Impiego di cellule staminali autologhe da sangue periferico mobilizzate con Plerixafor nel trapianto di pazienti affetti da linfoma e mieloma multiplo. Angelo Ostuni Servizio di Immunoematologia e Medicina

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical

More information

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy

More information

Autologous SCT in FL No!

Autologous SCT in FL No! COSTEM 2011 Controversies in Stem Cell Transplantation and Cellular Therapies Berlin, September 10 th, 2011 Autologous SCT in FL No! Ulrich Dührsen Department of Hematology Follicular lymphoma Positioning

More information

BENDAMUSTINE IN HODGKIN LYMPHOMA

BENDAMUSTINE IN HODGKIN LYMPHOMA CONVEGNO REGIONALE SIE DELEGAZIONE REGIONALE EMILIA ROMAGNA ATTUALITA IN EMATOLOGIA BOLOGNA 06.03.2015 BENDAMUSTINE IN HODGKIN LYMPHOMA Dott.ssa Cinzia Pellegrini Istituto di Ematologia e Oncologia Medica

More information

Hematopoietic Stem-Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Stem-Cell Transplantation for Hodgkin Lymphoma Hematopoietic Stem-Cell Transplantation for Hodgkin Lymphoma Policy Number: Original Effective Date: MM.07.015 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 03/22/2013 Section: Transplants

More information

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma 8 Karen S. Fernández and Pedro A. de Alarcón University of Illinois, College of Medicine at Peoria Children s Hospital of Illinois, USA 1.

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

HEMATOLOGY Board Review Manual

HEMATOLOGY Board Review Manual Volume 7, Part 4 November 2012 HEMATOLOGY Board Review Manual Advanced-Stage and Relapsed/ Refractory Hodgkin Lymphoma HEMATOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician

More information

New Targets and Treatments for Follicular Lymphoma

New Targets and Treatments for Follicular Lymphoma Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,

More information

E Aurlien, H Holte, A Pharo, S Kvaløy, E Jakobsen, EB Smeland and G Kvalheim. Summary:

E Aurlien, H Holte, A Pharo, S Kvaløy, E Jakobsen, EB Smeland and G Kvalheim. Summary: Bone Marrow Transplantation, (1998) 21, 873 878 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide

More information

Radiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin

Radiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Treatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center

Treatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop

More information

Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX

Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX Best of ASCO 2011 Lymphoma Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX RCHOP21 in DLBCL (GELA LNH-98.5 Study) Survival Probability OS (N = 399)

More information

Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.

Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D. 2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure

More information

Iranian Journal of Blood & Cancer. Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children

Iranian Journal of Blood & Cancer. Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children Oberlin O et al. IJBC 2015; 7(5): 206-212 Iranian Journal of Blood & Cancer Journal Home Page: www.ijbc.ir Review Article Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children Odile Oberlin*,

More information